Thus, in combination of therapeutic strategies that aim to inhibit autophagy in patients treated with conventional chemotherapy or novel targeted therapy with EGFR-TKIs represents a promising approach with higher efficacy for cancer patients. This evidence concerns the gene EGFR and cancer.